High-Dose Melphalan With Autologous Stem-Cell Rescue in Metastatic Rhabdomyosarcoma

Abstract

The addition of a high-dose alkylating agent to consolidation therapy may have prolonged progression-free survival in this poor-risk patient group, but it did not significantly improve the ultimate outcome.